Clinical Trials

Phase 4 Active not recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT04108208 2026-03-16

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

75 enrolled 9 charts

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05114746 2026-03-16

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

87 enrolled

Prostatic Neoplasms

NCT06056830 2026-03-16

CLARIFY

383 enrolled

Prostatic Neoplasms

NCT06651632 2026-03-16

WATER IV PCa

Phase NA Recruiting

280 enrolled

Prostatic Neoplasms

NCT06780670 2026-03-16

PSMAcTION

Phase 2/3 Recruiting

443 enrolled

Prostatic Neoplasms

NCT07103018 2026-03-16

STRIKE-001

144 enrolled

GenitourinaryLymphoidOther hematologic neoplasm

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT07474051 2026-03-16

PERSIST

Enrolling by invitation

178 enrolled

Prostatic Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms

NCT03523442 2026-03-13

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

19 enrolled

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04557059 2026-03-13

PRIMORDIUM

693 enrolled

Prostatic Neoplasms

NCT04577833 2026-03-13

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Prostatic Neoplasms

NCT04644770 2026-03-13

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

144 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT04662580 2026-03-13

ARX517

183 enrolled

Prostatic Neoplasms

NCT05022849 2026-03-13

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

15 enrolled

Prostatic Neoplasms

NCT06925737 2026-03-13

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT07082920 2026-03-13

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

140 enrolled

Prostatic Neoplasms

NCT07319871 2026-03-13

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

40 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Prostatic Neoplasms

NCT04585750 2026-03-12

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Phase 1/2 Recruiting

300 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04905069 2026-03-12

SABRE

Phase NA Active not recruiting

500 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologic

Neoplasms, Prostatic Neoplasms

NCT05417594 2026-03-12

CERTIS1

Phase 1/2 Recruiting

695 enrolled

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06451614 2026-03-12

HYDROSPACE

Phase NA Active not recruiting

230 enrolled

Prostatic Neoplasms

NCT06511141 2026-03-12

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Phase NA Recruiting

150 enrolled

Phase 1 Not yet recruiting

Prostatic Hyperplasia, Prostatic Neoplasms, Urinary Bladder, Overactive

NCT07468396 2026-03-12

A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer

65 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Prostatic Neoplasms

NCT07468708 2026-03-12

The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer

30 enrolled

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04720157 2026-03-11

PSMAddition

1,145 enrolled

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04821622 2026-03-11

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

599 enrolled

Prostatic Neoplasms

NCT06136650 2026-03-09

MK-5684-004

1,314 enrolled

Prostatic Neoplasms

NCT06533059 2026-03-09

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

BreastGenitourinaryGynecologic

110 enrolled

Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04221542 2026-03-06

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

479 enrolled

Bites and Stings, Prostatic Neoplasms

NCT06104449 2026-03-06

MK-5684-005

6 enrolled

Prostatic Neoplasms

NCT06691984 2026-03-06

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

675 enrolled

Neoplasms, Prostatic Neoplasms

NCT06985238 2026-03-06

Stratagen Quantitative Prostate MRI Platform Pilot Study

Phase NA Recruiting

75 enrolled

Prostatic Neoplasms

NCT07114601 2026-03-06

OMNIRAY

BreastGastrointestinalGenitourinaryGynecologic

421 enrolled

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07181161 2026-03-06

SEACLIFF

Phase 1/2 Recruiting

177 enrolled

Prostatic Neoplasms

NCT07454603 2026-03-06

PROSTest_STRAT

Not yet recruiting

1,500 enrolled

Disease, Prostatic Neoplasms

NCT07455058 2026-03-06

VAPOR-LTR

Not yet recruiting

2,500 enrolled

Prostatic Neoplasms

NCT05999968 2026-03-05

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Phase 1 Completed

10 enrolled

Prostatic Neoplasms

NCT06257264 2026-03-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

258 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07290270 2026-03-05

PSMAreal

Recruiting

170 enrolled

Prostatic Neoplasms

NCT06551324 2026-03-04

MEVPRO-1

600 enrolled

Prostatic Neoplasms, Recurrence

NCT07028853 2026-03-04

MEVPRO-3

1,000 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05546268 2026-03-03

Study of Oral MRT-2359 in Selected Cancer Patients

174 enrolled

BreastGenitourinaryLymphoidThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Lymphoma, Large B-Cell, Diffuse, Small Cell Lung Carcinoma

NCT05849298 2026-03-03

PSMACare

Phase 2 Active not recruiting

49 enrolled

Prostatic Neoplasms

NCT07005154 2026-03-03

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Phase 2 Recruiting

218 enrolled